Implicancias de la pandemia por COVID-19 y el aislamiento social sobre el perfil cardiometabólico de una cohorte de individuos en la Ciudad de Buenos Aires / Implications of the COVID-19 Pandemic and Social Isolation on the Cardiometabolic Profile of a Cohort of Individuals from the City of Buenos Aires

RESUMEN Introducción : La pandemia por COVID-19 ha conmocionado a la humanidad. Durante la misma, la necesidad de aislamiento social ha fomentado la baja adherencia a un estilo de vida saludable en muchos individuos. Sin embargo, existe poca evidencia del impacto metabólico que ha tenido la pandemia por COVID-19 en nuestro medio. Objetivos : Evaluar el impacto del aislamiento social producido por la pandemia COVID-19 sobre el peso corporal y los pará metros cardiometabólicos de una población de adultos en la Ciudad Autónoma de Buenos Aires. Materiales y métodos : En un diseño observacional, se analizaron los datos de pacientes (pac.) que asistieron a un programa de prevención y promoción de salud en la Ciudad de Buenos Aires. Se individualizaron datos de participantes que concurrieron a realizarse estudios en el año 2019 y repitieron los mismos en el año 2021. Los registros médicos se utilizaron como fuente para la recopilación de datos generales, medidas antropométricas y valores de laboratorios. Se utilizaron los criterios NCEP para definir la presencia de Síndrome Metabólico (SM). Resultados : Se identificaron un total de 558 pac. con evaluaciones disponibles en 2019 y 2021. La edad promedio de la población fue 52,2 ± 12,8 años, con 41% de mujeres. Se observó un incremento en el peso corporal (82,1 ± 17,7 kg vs. 83,1 ± 18,5kg; p <0,0001) y del índice de masa corporal (29,4 ± 5,4 vs. 29,8 ± 5,7, p <0,0001). También se observaron incrementos en la presión arterial sistólica (123,1 ± 15,1 mmHg vs. 126,6 ± 16,3 mmHg; p <0,0001) y diastólica (77,7 ± 9,3 mmHg vs. 79,6 ± 9,4 mmHg; p <0,0001). Dentro de los parámetros de laboratorio, se evidenció un incremento en los valores de glucemia plasmática, con mediana y rango intercuartilo (RIC) de 95 (89-103 mg/dL) vs. 99 (92-107 mg/dL), p <0,0001; y descenso del colesterol HDL (51,8 ± 12,7 mg/dL vs. 49,3 ± 12,8 mg/dL; p <0,00001). No se observaron cambios en el colesterol LDL (116,4 ± 32,6 mg/dL vs. 116,1 ± 34 mg/dL; p = NS), colesterol total (194,9 ± 37,4 vs. 193 ± 39,6 mg/dL; p=NS) o la concentración de triglicéridos, con mediana (RIC) de 114,5 (83,2-162,7 mg/dL) vs 118 (88-169 mg/dL), p=NS. Esto se acompañó de un au mento de la prevalencia de SM (21,5% vs 34%; p<0,0001). También se incrementó la proporción de pac. con placas a nivel carotídeo (35,8% vs. 40,5%; p <0,01). El 18,8% de los pac. incrementaron su peso corporal más del 5%. Esta población estuvo representada por pac. más jóvenes (47,6 ± 14 años vs. 53,3 ± 12 años; p< 0,0001), y se observó correlación inversa entre edad y magnitud del incremento del peso (r =-0,1; p<0,02). Conclusiones : El aislamiento social, durante la pandemia COVID-19, mostró tener importantes consecuencias en los factores de riesgo de la población estudiada. Las implicancias prospectivas de estos hallazgos podrían verse en los próximos años, si estas alteraciones metabólicas no se revierten.

ABSTRACT Background : The COVID-19 pandemic has shocked humanity. During the pandemic, the need for social isolation has encouraged low adherence to a healthy lifestyle in many individuals. However, evidence of the metabolic impact of COVID-19 pandemic on our field is scarce. Objective : To evaluate the impact of social isolation produced by the COVID-19 pandemic on the body weight and the cardio metabolic parameters of an adult population in the Autonomous City of Buenos Aires. Methods : Based on an observational design, we analyzed the data from patients who attended a prevention and health pro motion program in the City of Buenos Aires. Data from participants who attended for testing in 2019 and repeated testing in 2021 were individualized. Medical records were used as source for collecting general data, anthropometric measurements, and laboratory values. The National Cholesterol Education Program (NCEP) criteria were used to define the presence of metabolic syndrome (MS). Results : A total of 558 patients with available evaluations in 2019 and 2021 were identified. The average age of the population was 52.2 ± 12.8 years, and 41% was female. An increase in body weight (82.1 ± 17.7 kg vs. 83.1 ± 18.5 kg; p<0.0001) and body mass index (29.4 ± 5.4 vs. 29.8 ± 5.7, p <0.0001) was observed. Increases in systolic (123.1 ± 15.1 mmHg vs. 126.6 ± 16.3 mmHg; p <0.0001) and diastolic (77.7 ± 9.3 mmHg vs. 79.6 mmHg± 9.4 mmHg, p <0.0001) blood pressure values were also observed. As regards the laboratory parameters, we noted an increase in plasma glucose levels with a median and an interquartile range (IQR) of 95 (89-103 mg/dL) vs. 99 (92-107 mg/dL), p <0.0001, and a decrease in HDL cholesterol (51, 8 ± 12.7 mg/dL vs. 49.3 ± 12.8 mg/dL, p<0.0001). No changes were observed in LDL cholesterol (116.4 ± 32.6 mg/dL vs. 116.1 ± 34 mg/dL; p=NS), total cholesterol (194.9 ± 37.4 vs. 193 ± 39.6 mg/dL; p=NS) or triglyceride levels, with a median and IQR of 114.5 (83.2-162.7 mg/dL) vs. 118 (88-169 mg/dL; p=NS). This was accompanied by an increased prevalence of MS (21.5% vs. 34%; p<0.0001). The proportion of patients with carotid plaques also increased, without reaching statistical significance (36.4% vs. 40.7%; p=NS). Besides, it was observed that 18.8% of the patients increased their body weight by more than 5%. This population was represented by younger patients (47.6 ± 14 years vs. 53.3 ± 12 years; p< 0.0001) showing a reverse correlation between age and scope of weight increase (r=-0.1; p<0.02). Conclusion : Social isolation during the COVID-19 pandemic was shown to have important consequences on the risk factors of the population studied. The prospective implications of these findings might become apparent in the next few years if these metabolic alterations are not reversed.

Evaluación del perfil metabólico y prevalencia de enfermedad cardiovascular en los ex combatientes de la guerra de Malvinas / Evaluation of the metabolic profile and prevalence of cardiovascular disease in former combatants of the Malvinas war

Resumen Introducción: Se ha informado que los veteranos de guerra están más expuestos a factores de riesgo cardiovascular. El objetivo del presente trabajo fue establecer los factores de riesgo, el perfil cardiometabólico y la prevalencia de enfermedad cardiovascular de un grupo de excombatientes de la Guerra de Malvinas (HdeM). Métodos: En un diseño caso-control se analizaron los datos de 799 HdeM y se compararon 799 controles de misma edad. La muestra se seleccionó de los participantes del Programa de Prevención de Salud Cardiovascular de la Fundación Favaloro, entre enero de 2017 y diciembre de 2019. Resultados: La edad promedio fue 56.9 ± 3.9 años. Se observó un aumento del peso entre los HdeM (91.3 ± 16.6 kg vs. 88.2 ± 14.7 kg; p = 0.0001). Se observó mayor frecuencia de hipertensión arterial en HdeM (42% vs. 34%; p < 0.001) y diabetes mellitus (15.1% vs. 10.4%; p < 0.005). El síndrome metabólico fue más prevalente en HdeM (49.2% vs. 39.7%; p = 0.0001). Se observó que el antecedente de infarto agudo de miocardio fue más frecuente entre los HdeM (3.6% vs. 2%; p < 0.05), con similar prevalencia de ACV (1.2% vs. 1%; p = ns), angioplastia corona ria (3.2% vs. 2.1%; p = ns) o cirugía de revascularización miocárdica (0.8% vs. 0.4%; p = ns). Discusión: Los HdeM mostraron mayor prevalencia de factores de riesgo, síndrome metabólico e infarto agudo de miocardio. Es importante tener en cuenta este aumento de riesgo para maximizar las estrategias de prevención cardiovascular en los excombatientes.

Abstract Introduction: It has been reported in different parts of the world that war veterans are more exposed to cardio vascular risk factors. The objective of this study was to establish the risk factors, the cardiometabolic profile and the prevalence of cardiovascular disease in a group of ex-combatants of the Malvinas War (HdeM). Methods: In a case-control design, data from 799 HdeM were analyzed and compared with 799 controls matched by age. The sample was selected from the participants of the Cardiovascular Health Prevention Program of the Favaloro Foundation, between January 2017 and December 2019. Results: The average age was 56.9 ± 3.9 years. An increase in weight was observed among the HdeM (91.3 ± 16.6 kg vs. 88.2 ± 14.7 kg; p = 0.0001). A higher frequency of arterial hypertension (42% vs. 34%; p < 0.001) and diabetes mellitus (15.1% vs. 10.4%; p < 0.005) was observed in HdeM. Metabolic syndrome was also more prevalent in HdeM (49.2% vs. 39.7%; p = 0.0001). It was observed that the history of acute myocardial infarction was more frequent among the HdeM (3.6% vs. 2%; p < 0.05), with a similar prevalence of stroke (1.2% vs. 1%; p = ns), coronary angioplasty (3.2% vs. 2.1%; p = ns) or myocardial revascularization surgery (0.8% vs. 0.4%; p = ns). Discussion: The HdeM showed an increase in the frequency of risk factors, metabolic syndrome and acute myocardial infarction. It is important to take this increased risk into account in order to maximize cardiovascular prevention strategies in ex-combatants.

Estudio genético de hipercolesterolemia familiar en una población hospitalaria de la Ciudad de Buenos Aires / Genetic Testing of Familial Hypercholesterolemia in a Hospital-Based Population of the City of Buenos Aires

RESUMEN: Introducción: La hipercolesterolemia familiar es una hiperlipidemia primaria. Se trata de un trastorno genético autosómico dominante del metabolismo de las lipoproteínas, caracterizado por concentraciones plasmáticas elevadas de colesterol unido a lipoproteínas de baja densidad y presencia de xantomas tendinosos, y está asociado con el desarrollo prematuro de enfermedad cardiovascular. Objetivos: Investigar la presencia de mutaciones en el principal gen asociado al desarrollo de hipercolesterolemia familiar (LDLR) en un grupo de pacientes identificados como "casos índices", de entre aquellos que concurren al Servicio de Lípidos del Hospital Universitario Fundación Favaloro con diagnóstico clínico de hipercolesterolemia familiar. Determinar la composición ancestral de la población estudiada. Material y métodos: Se estudió una población de 38 pacientes con diagnóstico clínico de hipercolesterolemia familiar. La región codificante y las zonas intrónicas adyacentes del gen LDLR se secuenciaron automáticamente por el método de Sanger. Se investigó el componente ancestral de la población estudiada a partir del análisis de 46 marcadores informativos de ancestralidad (AIM-Indel). Resultados: Se identificaron 50 variantes diferentes, de las cuales el 48% se consideraron patogénicas. Se logró establecer una correlación genotipo-gravedad del fenotipo en el 60,5% de los pacientes estudiados. El componente ancestral de la población estudiada fue predominantemente europeo, seguido de un componente nativo-americano y, en menor proporción, africano. Conclusiones: El análisis genético por secuenciación del gen LDLR en pacientes identificados como "casos índices" con diagnóstico clínico de hipercolesterolemia familiar permite correlacionar el dato genético con la gravedad del fenotipo observado clínicamente y efectuar un diagnóstico en cascada en los miembros de la familia que presentan los criterios de inclusión considerados.

ABSTRACT: Background: Familial hypercholesterolemia is a primary hyperlipidemia. It is an autosomal dominant genetic disorder of lipoprotein metabolism, characterized by elevated plasma low-density lipoprotein cholesterol and presence of tendon xanthomas, and is associated with early cardiovascular disease. Objectives: The aim of this study was to investigate the presence of mutations in the main gene associated with the development of familial hypercholesterolemia (LDLR) in a group of patients identified as "index cases" attending the Lipid Clinic of the Hospital Universitario Fundación Favaloro with clinical diagnosis of familial hypercholesterolemia. The ancestral composition of the study population was determined. Methods: We evaluated 38 patients with clinical diagnosis of familial hypercholesterolemia. Mutation screening of the LDLR gene coding regions and adjacent intronic areas was performed using Sanger sequencing. The ancestral component of the study population was investigated using 46 ancestry inference markers (AIM-Indel). Results: Fifty different variants were identified, 48% of which were considered pathogenic. A genotype-phenotype severity correlation was established in 60.5% of the patients evaluated. The ancestral component of the study population was predominantly European, followed by native-American and African in lower proportion. Conclusions: Genetic testing by LDLR gene sequencing in patients identified as "index cases" with clinical diagnosis of familial hypercholesterolemia allows the correlation between the genetic information and the severity of the clinical phenotype to a cascade testing of the family members presenting the inclusion criteria considered.

La rosuvastatina atenúa la progresión de la estenosis aórtica generada por hipertensión arterial, independientemente de sus efectos hipolipemiantes / Rosuvastatin Slows the Progression of Aortic Stenosis Caused by Hypertension Regardless of Its Lipid-Lowering Effects / Rosuvastatin Slows the Progression of Aortic Stenosis Caused by Hypertension Regardless of Its Lipid-Lowering Effects

Introducción Existe evidencia epidemiológica que vincula factores de riesgo cardiovascular con la estenosis valvular aórtica. Recientemente se ha demostrado el desarrollo de estenosis valvular aórtica en un modelo de hipertensión arterial en animales. Planteamos la hipótesis de que el tratamiento con rosuvastatina modifica esta transformación. Objetivo Evaluar el efecto de la rosuvastatina sobre el desarrollo de estenosis valvular aórtica. Material y métodos Se instrumentaron conejos NZ machos (n = 43) con el modelo 1-riñón 1-clip de Goldblatt para generar hipertensión arterial. Los animales fueron aleatorizados a: HT (n = 17) que no recibió otro tratamiento, HT+R (n = 14) tratado con rosuvastatina 2,5 mg/kg/día y HT+R+C (n = 12) tratado con rosuvastatina 2,5 mg/kg/día + suplemento de colesterol dietético para mantener los niveles basales de colesterol plasmático. Un grupo control (GC) fue sometido a cirugía simulada (n = 15). Las características de la válvula aórtica se midieron por ecografía en condiciones basales y a los 3 y a los 6 meses de hipertensión arterial. Resultados A los 6 meses de seguimiento, los incrementos de PAS y PAD fueron más elevados en HT (49% y 40%, respectivamente; p < 0,001) en comparación con los grupos tratados con rosuvastatina (PAS = 23% y 25%; PAD = 28% y 26%; p < 0,001 para HT+R y HT+R+C, respectivamente). El colesterol total se redujo el 45,7% (p < 0,01) sólo en HT+R. El espesor valvar se incrementó en HT (0,50 ± 0,01 vs. 0,62 ± 0,02 mm; p < 0,01), sin mostrar diferencias en HT+R y HT+R+C. Finalmente, el área valvular aórtica mostró una reducción en HT (0,277 ± 0,024 vs. 0,208 ± 0,014 cm²; p < 0,05), sin cambios en HT+R y HT+R+C y un aumento no significativo en el GC (0,264 ± 0,022 vs. 0,32 ± 0,016 cm²; p = 0,07). Conclusiones La rosuvastatina atenúa la progresión de la estenosis valvular aórtica generada por hipertensión arterial. Esta protección podría ser mediada por efectos no hipolipemiantes de estas drogas.

Background There is epidemiological evidence associating cardiovascular risk factors with aortic valve stenosis. The development of aortic valve stenosis has been recently demonstrated in a hypertensive animal model. We hypothesize that treatment with rosuvastatin modifies this transformation. Objective To evaluate the effect of rosuvastatin on the development of aortic valve stenosis. Material and Methods Hypertension was induced in 43 male NZ rabbits by a onekidney, one-clip Goldblatt procedure. The animals were randomly assigned to 3 groups: HT (n=17) without treatment; HT+R (n=14) treated with rosuvastatin 2.5 mg/kg/day and HT+R+C (n=12) treated with rosuvastatin 2.5 mg/kg/day + cholesterol-enriched diet to keep baseline cholesterol levels. A control group (CG) underwent sham surgery (n=15). The characteristics of the aortic valve were measured by echocardiography at baseline, 3 and 6 months after inducing hypertension. Results After 6 months of follow-up, SBP and DBP presented greater increase in the group HT (49% and 40%, respectively; p<0.001) compared to groups treated with rosuvastatin (SBP = 23% and 25%; DBP = 28% and 26%; p <0.001 for HT+R and HT+R+C, respectively). Total cholesterol decreased by 45.7% (p <0.01) only in HT+R group. The aortic valve became thickened in the HT group (0.50 ± 0.01 vs. 0.62± 0.02 mm; p <0.01); there were no significant differences in HT+R and HT+R+C. Finally, the aortic valve area was reduced in HT (0.277 ± 0.024 vs. 0.208 ± 0.014 cm² ; p <0.05), had no differences in HT+R and HT+R+C, and presented a non-significant increase in CG (0.264 ± 0.022 vs. 0.32± 0.016 cm²; p=0.07). Conclusions Rosuvastatin slows the progression of aortic valve stenosis caused by hypertension. This protection might be independent of the lipid-lowering effect of the drug.

Seguimiento de pacientes sometidos a cirugía cardiovascular: impacto de la educación en la prevención secundaria / Follow-up of patients submitted to cardiovascular surgery: impact of teaching on the secondary prevention

Cardiac rehabilitation programs (CRP), include exercise training, medical advice and education related to cardiovascular pathologies, psychosocial support and behavioral characteristics. This approach shows a sustained positive impact over the cardiovascular risk factors, the physical training and the health-related quality of life of the patients and on adherence to dietary recommendations. During the 2004 the authors started the implementation of the Integral Teaching Program (ITP), focused to convalescent patients after a cardiovascular event and with the purpose to enter in a plan of cardiac rehabilitation and secondary preventions with exercise training programs and with a multidisciplinary approach. The aim of this report was to describe the results of the ITP in a cohort of patients submitted to cardiovascular surgery. In a second term, the impact of the ITP will be measured including the total and partial adherence to the different planes of cardiac rehabilitation programs and the management of vascular risk factors. Also it was studied the improvement in physiological outcomes and health-related quality of life in patients with acute myocardial infarction.

Categorización del síndrome metabólico de acuerdo con las variables que lo constituyen y su relación con la insulino-resistencia / Consensus definition of the metabolic syndrome and diagnostic criteria for identification and its relationshipo with the insulin-resistance syndrome

In recent years, the cardiovascular prevention has found a new clinical tool: the metabolic syndrome (MS). Arised in the observation of associations between risk factors, it is recognized as the clinical manifestation of insulin resistance. In the course of time, it was demonstrated that the presence of MS possess a prognostic value to predict death, nonfatal acute myocardial infarction, vascular stroke and the development of diabetes... The relationshipo to insulin resistance and diagnostic criteria for identification of the metabolic syndrome are given in the article.

Angioplastía programada en octogenarios con enfermedad coronaria crónica. Resultados hospitalarios y en el seguimiento alejado / Programmed angioplasty in the elderly with chronic coronary disease

Cardiac vascular disease is the main cause of death in the elderly, and this factor is closely related to the increase and severity of the ischemic cardiopathy... The aim of the present report is to show the hospitalary results and the late follow-up in a population of patients older than 80 years, submitted to coronary angioplasty. It is concluded that the revascularization by mean of an elective angioplasty is a valid option for persons age 80 or older, with chronic ischemic cardiopathy, resulting in our experience in a high rate of primary success, and with an acceptable rate of complications